



MedinCell: inclusion of first participants in new Covid-19 prophylaxis clinical trial SAIVE

Euronext: MEDCL • Montpellier - France • March 28, 2022 • 5:45 pm (CEST)

The first participants of the SAIVE study have been administered last Friday

SAIVE is a 400-participant, multicenter, randomized, double-blind, placebo-controlled study with an independent Data Monitoring Committee, conducted in the European Union

Interim data are expected mid 2022

SAIVE aims at validating the efficacy in prophylaxis against Covid-19 of administration of Ivermectin in oral daily form

It is part of MedinCell's program to develop a subcutaneous injection that could offer more than 3 months of protection against Covid-19 and its variants

SAIVE follows a Phase 1 clinical study conducted by MedinCell that successfully confirmed the safety of daily, oral Ivermectin administration over a long period of time

"We develop this program in accordance with the highest ethical standards and robust scientific principles, far from polemics, said Joël Richard, Chief Development Officer at MedinCell. Ivermectin has many modes of action identified and is not only a broad-spectrum antiparasitic agent. There is favorable data published about the prophylactic efficacy of Ivermectin against Covid-19 that must be confirmed by clinical studies conducted in accordance with regulatory authorities' standards. Oral daily administration was chosen to simulate the pharmacokinetic profile, i.e. the circulating drug concentration in the blood, from our long-acting injectable formulation. The data from SAIVE will be analyzed by an independent Data Monitoring Committee and will help inform its future development steps."

MedinCell's program aims at protecting against Covid-19 with a subcutaneous injection of a long-acting formulation of Ivermectin available in the form of a pre-filled syringe, ready-to-use, with 24-month stability at room temperature. MedinCell's BEPO® technology will allow the formation of a small subcutaneous depot, fully bioresorbable, at the time of injection. It will act as a biodegradable mini pump that releases Ivermectin regularly until it is completely bio resorbed.

A long-acting injectable formulation of Ivermectin could be an additional tool to protect from Covid-19, especially for non-respondents to vaccines, such as immunocompromised people and elderly, and for those with poor access to vaccines or potential treatments.

A more than 3-month active formulation is ready to enter regulatory development.

The safety of the daily administered Ivermectin dose set at 100 µg/kg was validated during a Phase 1 clinical study conducted by MedinCell (press release: www.medincell.com/en/2021/04/19/clinical-trial-conducted-by-medincell-confirms-the-safety-of-continuous-administration-of-ivermectin/)

About the SAIVE study

| | |
|-------------------------|---|
| Study title | SAIVE, A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention |
| Description | A multicenter, randomized, double-blind, placebo-controlled trial comparing continuous administration of Ivermectin (in regular, daily, oral form) vs placebo in the prevention of COVID-19 infection as well as symptomatic development, in a close-contact population |
| Participants | 400 |
| Administration | Daily oral Ivermectin or placebo for 4 weeks |
| Dose | 200 µg/kg on Day 1, and then 100 µg/kg/day for Day 2 to Day 28 |
| Primary outcome measure | COVID-19 prophylaxis: proportion of laboratory-confirmed COVID-19 infections between baseline and Day 28 |

About MedinCell

MedinCell is a pharmaceutical company at premarketing stage that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. MedinCell collaborate with tier one pharmaceuticals companies and foundations to improve Global Health through new therapeutic options. Based in Montpellier, MedinCell currently employs more than 140 people representing over 25 different nationalities.
www.medincell.com

Contacts

MedinCell
David Heuzé
Head of communication
david.heuze@medincell.com
+33 (0)6 83 25 21 86

NewCap
Louis-Victor Delouvrier / Olivier Bricaud
Investor Relations
medincell@newcap.eu
+33 (0)1 44 71 94 94

NewCap
Nicolas Merigeau
Media Relations
medincell@newcap.eu
+33 (0)1 44 71 94 94

This press release contains forward-looking statements, including statements regarding Company's expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) its ability to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this press release relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities.

These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as "objective", "believe", "anticipate", "expect", "foresee", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", "potential", "should", "could" and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these

risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (the "AMF") pursuant to its regulatory obligations, including the Company's registration document, registered with the AMF on September 4, 2018, under number I.18-062 (the "Registration Document"), as well as in the documents and reports to be published subsequently by the Company. In particular, readers' attention is drawn to the section entitled "Facteurs de Risques" on page 26 of the Registration Document.

Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements.

This press release is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be subject to legal restrictions in certain jurisdictions. Persons who come to know about this press release are encouraged to inquire about, and required to comply with, these restrictions.